NCT01974570

Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects

A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 144 (actual)
• Sponsor: KGK Science Inc. · Industry
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Hypertension is an important risk factor of cardiovascular (CVD) and renal diseases. Epidemiological studies show that there is a direct relationship between blood pressure and CVD, and cardiovascular mortality increases progressively throughout the range of blood pressure, including the prehypertensive range. There is also evidence from cell and animal studies that shrimp tissue hydrolysates may have higher ACE inhibitory activity than other marine protein hydrolysates. It is hypothesized that Marealis RPC (refined peptide concentrate)will lower systolic blood pressure in subjects with elevated blood pressure.

Conditions

• Prehypertension

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Marealis refined peptide concentrate	2 tablets, once per day before noon
DIETARY_SUPPLEMENT	Placebo	2 tablets, once per day before noon

Timeline

• Start date: 2013-11-01
• Primary completion: 2015-11-01
• Completion: 2015-11-01
• First posted: 2013-11-01
• Last updated: 2015-12-24

Locations

13 sites across 4 countries: United States, Canada, Czechia, Germany